Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Synribo (omacetaxine mepesuccinate; Teva/Hospira) Drugs Analysis -

Research and Markets
Posted on: 19 Feb 18

The "Drugs Analysis: Synribo" report has been added to's offering.

Synribo (omacetaxine mepesuccinate; Teva/Hospira) is a subcutaneously formulated, semisynthetic form of homoharringtonine, a naturally occurring alkaloid. In vitro studies show that Synribo binds to the ribosomal A-site cleft, inhibiting synthesis of a number of key oncoproteins. These oncoproteins include mcl-1 (an apoptosis inhibitor), cyclin-D1 (a promoter of cell proliferation), and c-Myc (a cell differentiation inhibitor).

Synribo has suffered due to its late entrance into the chronic myeloid leukemia (CML) market and an unfavorable subcutaneous administration route compared to other marketed drugs. The drug has displayed activity against T315I mutation-positive disease, but Iclusig (ponatinib; Takeda/Incyte/Otsuka) displays similar activity and is available in an orally administered formulation. Therefore, Synribo will continue to see only minimal uptake in CML.

Key Topics Covered:

List of Figures

Figure 1: Synribo for CML - SWOT analysis

Figure 2: Drug assessment summary of Synribo for CML

Figure 3: Drug assessment summary of Synribo for CML

List of Tables

Table 1: Synribo drug profile

Table 2: Synribo pivotal trial data in CML

For more information about this report visit

View source version on

Business Wire

Last updated on: 19/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.